Do you want to read an ai analysis comparing how historical

New Post Public Reply Private Reply Replies (0) Message Board
twinter11 Dream big #164273
821
Do you want to read an ai analysis comparing how historical mouse models are difficult to quantify for cc5 block and a comparison to how smc did the study. And the results of the smc study Etc etcI understand if nobody does. But there might be someone interested.
Disregard  anything that feels like exaggeration 
Those blood vessel reduction photos were pretty impressive huh?
I thought so when I looked at them back then

Ai
"The dynamic you are describing cuts straight to the primary crisis of translation in modern medicine: why conventional mouse models fail to capture human biology, and why the specific physics of a human-targeted monoclonal antibody require humanized models to prove their clinical worth. 

The baseline rules of cross-species immunology explain why standard animal models provide an inaccurate map of human tissue, and how the Lindner et al. Cleveland Clinic model bridges that gap to demonstrate the true power of a physical CCR5 blockade. 

1. The Translatability Problem: Why Normal Mice Don't Recreate Human Tissue
The standard laboratory mouse strain (like a wild-type C57BL/6 or BALB/c) possesses a completely distinct immunological and vascular blueprint from a human: 

* Receptor Divergence: While human and murine CCR5 share general structural layouts, their precise amino acid sequences—especially within the extracellular loops (ECL1 and ECL2)—differ significantly.
* The Blocking Conflict: A humanized, elite monoclonal antibody like leronlimab is highly target-specific. It is engineered exclusively to recognize and allosterically bind to the human CCR5 protein architecture. If you inject it into a conventional mouse, the antibody cannot recognize the murine receptor loops; it floats harmlessly in the blood, resulting in a false signal of "no effect." 
* Immune Network Mismatch: As reviewed in recent computational translatability studies (such as TransComp-R frameworks), standard mice have vastly different immune cell ratios (e.g., highly neutrophil-dominant vs. human lymphocyte-dominant peripheral blood). They also express different immunoglobulin IgG classes and alternate matrix-metalloproteinase (MMP) kinetics. Attempting to trace a complex, human immune-to-stromal network like the THBS1/SPP1 macrophage axis or the Nature Aging bone marrow reset in a normal mouse is an exercise in statistical noise. 

 2. The Cleveland Clinic Breakthrough: How Humanized Xenografts Solve the Riddle
This is why Dr. Daniel J. Lindner’s team at the Cleveland Clinic utilized a highly sophisticated, multi-tiered Humanized Mouse Xenograft Model to secure their definitive data. 

[ THE PRECLINICAL TRANSLATABILITY JUNCTION ]

Conventional Murine Model Humanized Xenograft Model
(Standard C57BL/6 or BALB/c) (Immunocompromised + Engrafted)
│ │
▼ ▼
[ RECEPTOR MISMATCH LOOP ] [ THE HUMANIZED HOTSPOT ]
• Murine ECL1/ECL2 loops do • Human tumor cells + human
not bind human IgG4 mAbs. immune system cells engrafted.
• Monoclonal antibody fails • Direct target matching achieved.
to attach to cells. │
│ ▼
▼ [ DETERMINISTIC OUTPUT ]
FALSE INEFFECTIVE SIGNAL • ~87% Lung Metastasis Reduction
• 62% Peri-Tumoral Vessel Loss
• Causal Checkpoint Unmasking

To make the science translatable, the researchers used specialized, immunocompromised mice engrafted with both human tumor cells and human peripheral blood mononuclear cells (PBMCs). 

* Direct Target Matching: This humanization creates a living micro-ecosystem where the circulating monocytes, the infiltrating stroma, and the tumor masses express the exact human CCR5 receptor. For the first time, a human-targeted antibody can physically lock onto the receptor with 100% target occupancy inside a living organism. 

* Verifying the Physical Output: The moment the allosteric shield was introduced into this humanized environment, the results were definitive:
1. The ~87% reduction in lung metastatic burden proved that blocking human CCR5 physically arrests the actin-myosin motors of mobile cell vectors.
2. The 62% drop in peri-tumoral blood vessels proved that the immune-to-stromal chemokine cross-talk driving angiogenesis is human-specific and completely dependent on this axis.
3. The 1.84-fold reduction in target suppressor T-cells verified that the local immune checkpoint environment shifts exactly as the "Prime and Pair" model predicts". 

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 170

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 115

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 88

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 10

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 23

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 122

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 118

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 17

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 160

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 72

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading

Top 5 Most Recently Viewed Articles

Bladex Reports Impressive Q1 Earnings with Substantial Growth

Updated Category News Views 256

Bladex Financial Performance in Q1 Banco Latinoamericano de Comercio Exterior, S.A. (NYSE: BLX), commonly referred to as Bladex, has announced strong financial outcomes for the first quarter of the year. The bank recorded a net profit of $51.7 million, equating to $1.40 per share, reflecting a year-over-year increase of 1%. This impressive result has contributed to an...

Continue Reading
Opportunities Open Up at Linnet Corner for Seniors

Updated Category News Views 426

Exciting Housing Opportunities for Seniors The Housing Authority of the City of Alameda (AHA) is thrilled to announce the opening of a housing wait list for its newest community, Linnet Corner. Designed specifically for seniors aged 62 and older, this community will offer modern living options in a prime location. With proper access to public transportation, grocery...

Continue Reading
Vistra Corp's Future: Sustaining Growth and Performance

Updated Category News Views 426

Vistra Corp: A Look Ahead at Potential Growth in 2025 Vistra Energy Corp (NYSE: VST) has gained significant attention among investors due to its impressive performance. The company's stock experienced a remarkable 260% increase in value, cementing its position as the second-best performer in its sector. As we begin 2025, Vistra has already displayed positive momentum with...

Continue Reading
Relive Health's New Coral Gables Center Promotes Wellness

Updated Category News Views 346

Relive Health's New Coral Gables Location Set to Energize Wellness Relive Health is excited to announce the grand opening of its latest wellness center in Coral Gables. This expansion reflects the company's commitment to enhancing the health and vitality of communities through cutting-edge wellness solutions. A Comprehensive Wellness Experience This new clinic offers a...

Continue Reading
EssilorLuxottica and Meta Unveil Next-Gen AI Glasses in 2025

Updated Category News Views 456

Exciting Innovations in Wearable Technology EssilorLuxottica and Meta Platforms, Inc. have unveiled their latest advancements in the realm of AI glasses at the recent Meta Connect event. Building on their successful collaboration, these two industry leaders are set to redefine how consumers interact with technology through innovative wearables. The newest models,...

Continue Reading